Astria Therapeutics (NASDAQ:ATXS) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report released on Thursday,Benzinga reports. HC Wainwright currently has a $16.00 target price on the biotechnology company’s stock.

Other analysts have also issued reports about the stock. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. TD Cowen assumed coverage on Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 target price on the stock. Oppenheimer boosted their price target on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Price Performance

Astria Therapeutics stock traded down $0.74 during trading hours on Thursday, hitting $9.35. The stock had a trading volume of 132,323 shares, compared to its average volume of 613,292. Astria Therapeutics has a 1-year low of $4.26 and a 1-year high of $16.90. The stock has a market capitalization of $527.53 million, a price-to-earnings ratio of -4.44 and a beta of 0.71. The stock’s fifty day moving average is $11.44 and its two-hundred day moving average is $10.60.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). As a group, sell-side analysts anticipate that Astria Therapeutics will post -1.68 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ATXS. Quest Partners LLC boosted its position in shares of Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,112 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in Astria Therapeutics by 135.6% during the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 2,861 shares during the period. PDT Partners LLC acquired a new position in shares of Astria Therapeutics in the 3rd quarter valued at $140,000. SG Americas Securities LLC purchased a new stake in shares of Astria Therapeutics during the 3rd quarter valued at $155,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Astria Therapeutics during the 2nd quarter worth $171,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.